Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Lowered by Mizuho

Mizuho lowered shares of Vigil Neuroscience (NASDAQ:VIGL - Free Report) from a strong-buy rating to a hold rating in a report issued on Friday morning,Zacks.com reports.

VIGL has been the subject of a number of other research reports. Citigroup cut Vigil Neuroscience to a "market perform" rating in a research report on Thursday, May 22nd. William Blair cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Guggenheim set a $8.00 price objective on shares of Vigil Neuroscience and gave the company a "neutral" rating in a research report on Thursday, May 22nd. JMP Securities reissued a "market perform" rating on shares of Vigil Neuroscience in a research note on Thursday, May 22nd. Finally, HC Wainwright lowered their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Friday, March 14th. Nine equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, Vigil Neuroscience presently has a consensus rating of "Hold" and a consensus price target of $11.50.

Vigil Neuroscience Stock Down 0.1%

Shares of VIGL traded down $0.01 during mid-day trading on Friday, reaching $7.88. 2,108,758 shares of the company's stock were exchanged, compared to its average volume of 642,726. Vigil Neuroscience has a 52-week low of $1.31 and a 52-week high of $7.95. The company has a market cap of $367.78 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. The company has a 50-day simple moving average of $2.31 and a two-hundred day simple moving average of $2.31.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. As a group, equities research analysts predict that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BVF Inc. IL grew its holdings in Vigil Neuroscience by 121.3% in the first quarter. BVF Inc. IL now owns 4,013,633 shares of the company's stock valued at $7,144,000 after purchasing an additional 2,200,000 shares during the period. Aberdeen Group plc grew its position in Vigil Neuroscience by 226.3% during the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company's stock valued at $3,070,000 after acquiring an additional 1,196,048 shares during the period. Blair William & Co. IL lifted its stake in shares of Vigil Neuroscience by 219.1% in the 1st quarter. Blair William & Co. IL now owns 1,033,577 shares of the company's stock valued at $1,840,000 after purchasing an additional 709,677 shares in the last quarter. Woodline Partners LP grew its holdings in shares of Vigil Neuroscience by 239.1% during the 4th quarter. Woodline Partners LP now owns 488,756 shares of the company's stock worth $831,000 after purchasing an additional 344,614 shares during the period. Finally, 683 Capital Management LLC increased its position in Vigil Neuroscience by 24.3% during the 1st quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company's stock worth $3,097,000 after purchasing an additional 340,000 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.